SCHEMBL7528191

SCHEMBL7528191

[CH2]CN(C(=O)c1ccc(N(C)C)cc1)C(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 6/20 0.48
ALDH1A1 P00352 6/20 0.48
MAPT P10636 5/20 0.48
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
HDAC1 Q13547 5/20 0.46
HDAC6 Q9UBN7 5/20 0.46
HDAC3 O15379 3/20 0.46
HDAC4 P56524 3/20 0.46
HDAC7 Q8WUI4 3/20 0.46
HDAC2 Q92769 3/20 0.46
HDAC10 Q969S8 3/20 0.46
HDAC11 Q96DB2 3/20 0.46
HDAC8 Q9BY41 3/20 0.46
HDAC9 Q9UKV0 3/20 0.46
HDAC5 Q9UQL6 3/20 0.46
RAB9A P51151 4/20 0.43
NPC1 O15118 4/20 0.43
HTT P42858 1/20 0.43
CA2 P00918 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7531771 0.81 MEN1 (0.46) HPGDALDH1A1MAPTMEN1KMT2A
SCHEMBL7533635 0.79 ALDH1A1 (0.55) HPGDALDH1A1MAPTMEN1KMT2A
SCHEMBL2592951 0.79 CES2 (0.47) HPGDMAPTHDAC1HDAC6HDAC3
SCHEMBL7529748 0.75 MEN1 (0.57) HPGDALDH1A1MAPTMEN1KMT2A
SCHEMBL24783913 0.72 ALDH1A1 (0.67) HPGDALDH1A1MAPTMEN1KMT2A
SCHEMBL3300602 0.70 ALDH1A1 (0.64) HPGDALDH1A1MAPTMEN1KMT2A
SCHEMBL2462243 0.69 MEN1 (0.64) HPGDALDH1A1MAPTMEN1KMT2A
SCHEMBL13672145 0.69 MEN1 (0.54) HPGDALDH1A1MAPTMEN1KMT2A
SCHEMBL888713 0.69 ALDH1A1 (0.61) HPGDALDH1A1MAPTMEN1KMT2A
SCHEMBL18127339 0.69 MAPT (0.61) HPGDALDH1A1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020147331-A1 Methods for synthesis of oligonucleotides ISIS PHARMACEUTICALS, INC. 2002-10-10 US claimed
WO-2002062811-A2 IMPROVED METHODS FOR SYNTHESIS OF OLIGONUCLEOTIDES ISIS PHARMACEUTICALS, INC. (US) 2002-08-15 WO claimed
US-20020147331-A1 Methods for synthesis of oligonucleotides ISIS PHARMACEUTICALS, INC. 2002-10-10 US disclosed
WO-2002062811-A2 IMPROVED METHODS FOR SYNTHESIS OF OLIGONUCLEOTIDES ISIS PHARMACEUTICALS, INC. (US) 2002-08-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020147331-A1 Methods for synthesis of oligonucleotides RNGTT, TYMP, PNP HPGD 3858/4885ALDH1A1 4843/4885MAPT 3054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.